Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, discuss the relative benefits and risks of maintenance therapy in ovarian cancer with bevacizumab versus a PARP inhibitor.
Choosing Maintenance Therapy in Ovarian Cancer
Videos — August 18, 2020
Associate Chief Medical Officer
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
UCLA Health
Los Angeles, CA
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
The University of Arizona Cancer Center
Tucson, AZ
